Title | Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. |
Publication Type | Journal Article |
Year of Publication | 2008 |
Authors | Glodzik L, King KG, Gonen O, Liu S, de Santi S, de Leon MJ |
Journal | Prog Neuropsychopharmacol Biol Psychiatry |
Volume | 32 |
Issue | 4 |
Pagination | 1005-12 |
Date Published | 2008 May 15 |
ISSN | 0278-5846 |
Keywords | Adult, Aged, Aging, Alzheimer Disease, Cognition Disorders, Excitatory Amino Acid Antagonists, Female, Glutamic Acid, Hippocampus, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Male, Memantine |
Abstract | Glutamate (Glu) is associated with excitotoxic cell damage. Memantine modulates the glutamate induced excitotoxicity in Alzheimer's disease (AD). No information is available as to the influence of memantine on in vivo brain glutamate levels. Hippocampal Glu levels were measured in cognitively impaired and normal individuals (n=10) before and after 6 months of memantine treatment, using three dimensional high spatial resolution (0.5 cm(3) voxels) proton magnetic resonance spectroscopy at 3 T. These measurements were also repeated in a non-treated cognitively normal group (n=6). Treatment with memantine decreased Glu/Cr (creatine) ratio in the left hippocampal region. Memantine reduced hippocampal glutamate levels, which may be consistent with its anti-excitotoxic property. |
DOI | 10.1016/j.pnpbp.2008.01.016 |
Alternate Journal | Prog Neuropsychopharmacol Biol Psychiatry |
PubMed ID | 18343551 |
PubMed Central ID | PMC2789554 |
Grant List | R01 EB001015 / EB / NIBIB NIH HHS / United States M01 RR000096-458307 / RR / NCRR NIH HHS / United States M01RR00096 / RR / NCRR NIH HHS / United States EB01015 / EB / NIBIB NIH HHS / United States R01 EB001015-12 / EB / NIBIB NIH HHS / United States R01 NS050520-04 / NS / NINDS NIH HHS / United States P30 AG008051-189005 / AG / NIA NIH HHS / United States AG12101 / AG / NIA NIH HHS / United States R01 NS050520 / NS / NINDS NIH HHS / United States R01 AG022374 / AG / NIA NIH HHS / United States R01 AG012101-13 / AG / NIA NIH HHS / United States M01 RR000096 / RR / NCRR NIH HHS / United States NS050520 / NS / NINDS NIH HHS / United States P30 AG008051 / AG / NIA NIH HHS / United States R01 AG022374-02 / AG / NIA NIH HHS / United States P30 AG08051 / AG / NIA NIH HHS / United States R01 AG012101-14 / AG / NIA NIH HHS / United States AG 22374 / AG / NIA NIH HHS / United States R01 AG012101 / AG / NIA NIH HHS / United States R56 NS050520 / NS / NINDS NIH HHS / United States R01 AG012101-15 / AG / NIA NIH HHS / United States R01 EB001015-13A2 / EB / NIBIB NIH HHS / United States R01 AG022374-03 / AG / NIA NIH HHS / United States P30 AG008051-199005 / AG / NIA NIH HHS / United States AG0305 / AG / NIA NIH HHS / United States R01 AG022374-05 / AG / NIA NIH HHS / United States |
Related Institute:
Brain Health Imaging Institute (BHII)